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INTRODUCTION: Gender-specific differences have led to the androgen receptor (AR) being considered a possible
factor in the pathophysiology of urothelial carcinoma of the bladder (UCB), but the exact role remains unclear.
MATERIALS AND METHODS: The association of AR mRNA expression with clinicopathological features was
retrospectively analyzed in two previously described cohorts. The first cohort consisted of 41 patients with all
stages of UCB treated at Aarhus University Hospital, Denmark. The second cohort consisted of 323 patients with
muscle-invasive bladder cancer (MIBC) accumulated by the Cancer Genome Atlas (TCGA) Research Network.
RESULTS: AR mRNA expression is significantly higher in non-muscle-invasive bladder cancer (NMIBC) when
compared to MIBC (P = .0004), with no relevant changes within the different stages of MIBC. AR mRNA
expression was significantly associated with TCGA molecular subtypes (P b .0001). In the total cohort, there was
no association between AR expression and gender (P = .23). When analyzed separately, females showed a
significantly worse disease-free (P = .03) and overall survival (P = .02) when expressing AR mRNA above median
level, while the same was not observed for men. Multivariable Cox's regression analyses revealed AR mRNA
expression to be an independent prognosticmarker for disease-free survival inwomen (P = .007).CONCLUSIONS:AR
mRNA expression is significantly higher in NMIBC than in MIBC, while high AR mRNA expression is associated with
worse survival in females with MIBC. Further studies need to investigate the gender-specific role of AR in UCB.
Translational Oncology (2019) 12, 661–6682019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is















































































































sorothelial carcinoma of the bladder (UCB) is the ninth most
mmon cancer worldwide with an estimated 429,000 new cases and
5,000 deaths per year [1]. Men have a three to four times increased
sk of developing bladder cancer than women, even when accounting
r lifestyle and environmental factors [2,3]. On the other hand,
omen are more likely to have advanced tumors at the time of
agnosis as well as a worse outcome [4,5]. This has led to the
vestigation of sex hormones and sex hormone receptors as possible
ctors in the development of bladder cancer [6].
There is emerging evidence of the involvement of the androgen
ceptor (AR) and the androgen signaling pathway in urothelial
rcinoma [7]. An association between expression of AR and the
velopment of UCB could be demonstrated in numerous experiments
animals and human urothelial cell lines [8–12]. However, the
ognostic relevance of AR expression in UCB remains controversial.
hile some studies described an association between highAR expression
d increased tumor stage and grade as well as a worse survival [8,13],
her studies reported that tumor progression is accompanied by
creased AR expression [14,15]. Moreover, most studies found no
gnificant difference of AR expression in UCB betweenmale and female
tients [13,15,16]. The conflicting results of the previously cited studies
ight in part be attributed to immunohistochemistry as the main
ethod to determine AR expression, since immunohistochemistry is
sociated with high inter-observer variability depending on the
tibodies used and different cut-off values [16]. In a recent study, we
ere able to identify improved survival for patients with stageT1 bladder
ncer and high AR mRNA expression measured with quantitative
al-time polymerase chain reaction [17].
Additionally, an association between AR and the transcription factor
ATA3 was previously investigated in UCB by analogy with breast
ncer. Prior studies in breast cancer demonstrated that high co-
pression of GATA3 and AR was a key feature of the apocrine subtype
triple negative breast cancers, which is associated with improved
ognosis compared to other types of triple negative breast cancers [18].
UCB, previous preclinical studies in UCB cell lines showed that
ATA3 knockdown results in down-regulation of molecules that play a
otective role in bladder tumorigenesis and up-regulation of oncogenic
nes, thus suggesting a protective role of GATA3 in bladder cancer
9]. Moreover, GATA3 is considered one of the main markers to
aracterize luminal subtypes of UCB [20,21]. A prognostic
gnificance of GATA3 in UCB as well as a possible regulatory
teraction with androgens has previously also been suggested [19,22],
t further analyses are still necessary.
In the present study, we retrospectively investigated the association
AR mRNA expression with clinicopathological features, survival,
d GATA3 mRNA expression within two independent cohorts
presenting patients with all stages of UCB.
aterials and Methods
atient Population
In the present study we were given access to two previously
scribed cohorts for the analysis of AR mRNA expression.
The first cohort consisted of 41 patients with all stages of UCB
a – T4) at initial diagnosis originally treated by transurethral resection
the bladder (TURB) at the Department of Urology of the Aarhus
niversity Hospital. Informed consent was obtained from all patients,
d the protocols were approved by the scientific ethical committee of
arhus County and performed in accordance to corresponding approvedrgery and frozen in a guanidinium thiocyanate solution for
eservation of RNA. Only specimens containing at least 50% tumor
lls were used in this study which was previously suggested to be valid
r mRNA based subtyping in breast cancer studies [24–26]. A full-
nome expression analysis of 59,619 genes and expressed sequence tags
cluding sex hormone receptor genes was performed by high-density
igonucleotide microarrays (customized Affymetrix GeneChip, Santa
lara, CA) as previously described in more detail [23]. Data on tumor
age, tumor grade according to the 1973 WHO classification and AR
RNA expression was available for all patients. There were no data on
e and treatment modality and only limited data on nodal and
etastasis status. All patients of this cohort were included in the analysis
AR mRNA expression with tumor stage and grade.
The second cohort comprised 402 cases that were accumulated by
e Cancer Genome Atlas (TCGA) Research Network from 19 sites
7]. RNA-Seq (HiSeq) was used for whole genome analysis in tumor
mples as previously described [27]. Four molecular subtypes
ere defined in this cohort based on mRNA expression patterns
.e. TCGA subtypes): the subtypes I and II are described as luminal-
e, with subtype I being defined by FGFR3 alterations and elevated
GFR3 expression, while subtype II is characterized by ERBB2
utations and estrogen receptor beta (ESR2) enrichment. Subtypes
I and IV are described as basal-like, defined by increased expression
epithelial lineage genes and stem/progenitor cytokeratines, with
btype III showing higher mRNA expression of keratins and FGFR3
an subtype IV [27].
The clinical data as well as data on AR and GATA3 mRNA
pression for the TCGA cohort is publicly available at the cBioPortal
r Cancer Genomics website (http://www.cbioportal.org/study?id=
ca_tcga#clinical). The data set was downloaded on December 6th of
16 and was validated by K.A.H. onMarch 16th of 2017. Since most
tients in the TCGA cohort had MIBC, patients with stages T0 and
1 were excluded from the analysis. Aside from 10 patients who
ceived radiotherapy, the exact treatment modality was not docu-
ented. Therefore, we used a documented pN status as a surrogate for
rgical therapy. All patients with pNXwere excluded from the analysis,
were patients who received neoadjuvant therapy, definitive
diotherapy or had documented metastases. The final analysis set
nsisted of 323 patients. We then analyzed the association of AR
RNA expression in MIBC with tumor stage, tumor grade according
the WHO 2004 classification, nodal status, age, gender, smoking
atus, TCGA subtype as well as overall (OS) and disease-free survival
FS). We also decided to analyze the association between AR and
ATA3 mRNA expression, since an association was previously
ggested [19,22].
tatistical Methods
The Spearman's product–moment correlation coefficient rs was
ed to measure the strength and direction of the linear relationship
tween variables (tumor stage, grade, nodal status, gender, age,
oking status, GATA3 expression and TCGA subtype). In addition,
ilcoxon/Kruskal-Wallis was used to test the significance of the
fferences between these variables. Scatter plot and box plot analysis
ere used to describe AR mRNA expression depending on stage and
CGA subtype. Statistical analysis including Kaplan–Meier survival
alysis and multivariable Cox's regression analysis were performed
ith JMP SAS (SAS Institute, Cary, NC, USA) and Graph Pad Prism
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esults from the Aarhus Cohort
Clinicopathological characteristics of the Aarhus cohort are
mmarized in Table 1. Of the 41 patients, 29 had non-muscle-
vasive bladder cancer (NMIBC) and 12 had muscle-invasive bladder
ncer (MIBC). The median AR mRNA expression in this cohort was
.4. Since there were no data on treatment modality and only limited
ta on nodal and distant metastases, we did not analyze the association
tween AR mRNA expression and nodal status, metastasis and
rvival. Spearman's rank correlation and Wilcoxon/Kruskal-Wallis
sting revealed a statistically significant association between tumor
age (Chi2 = 14.48; P = .0059) but not tumor grade (Chi2 = −0.53;
= .46). Scatter plot analysis demonstrated a significantly lower AR
RNA expression pattern with increasing tumor stage, with the largest
p occurring between NMIBC and MIBC (P = .0004) (Figure 1).
here was no association between ARmRNA expression and gender in
e complete cohort. Median mRNA expression in females was almost
entical to males (52.93 vs 54.82) with similar range (Min/Max
males 18.84–192.45 vs Min/Max males 23.67–161.84). The analysis
stage dependent ARmRNA expression stratified by gender showed a
end towards higher AR mRNA expression in NMIBC, however,
cause of the small sample size containing only five women the gender
ecific analysis could not reveal any statistically meaningful results
upplementary Figure 1).
esults from the TCGA Cohort
A total of 79 patients were excluded (4 patients had NMIBC; 33 had
data on tumor stage; 41 had no data on nodal status; 10 had positive
etastases; 10 received neoadjuvant therapy; 10 received definitive
diotherapy; some patients had more than one exclusion criteria),
aving 323 patients with MIBC to be included into the AR mRNA
pression analysis. Figure 2 shows the flow chart representing the
clusion criteria. An additional 71 patients were excluded from the
alysis of DFS because of missing data, leaving a total of 252 patients
83male (72.6%) and 69 female (27.4%)) for inclusion in the analysis
the association of ARmRNAexpression andDFS. The characteristics
the patients included in the survival analysis are shown in Table 2.ble 1. Patient characteristics of the patients in the Aarhus cohort
tient characteristics n (%)























anSpearman's rank correlation demonstrated a significant positive
sociation between AR mRNA expression and GATA3 mRNA
pression (rs = 0.37; P b .0001) (Supplementary Figure 2). There
as no significant association between AR mRNA expression and
mor stage, grade WHO 2004, nodal status, age, gender, and
oking status in MIBC. Wilcoxon/Kruskal-Wallis testing revealed a
atistically significant association between the TCGA subtype and
R mRNA expression (Chi2:46.7; P b .0001) (Figure 3). AR
stribution is significantly lower in the basal subtypes III and IV

























Table 2. Patient characteristics of the 252 patients in the TCGA cohort with available follow-up
data on disease-specific survival divided by gender
Male Female
Total cohort n (%) 183 (100) 69 (100)
Tumor stage n (%)
T2 62 (33.9) 22 (31.9)
T3 95 (51.9) 38 (55.1)
T4 26 (14.2) 9 (13.0)
Tumor grade (WHO 2004) n (%)
Low grade 17 (9.3) 1 (1.5)
High grade 164 (89.6) 68 (98.6)
NA 2 (1.1) 0 (0)
Nodal status n (%)
pN+ 61 (33.3) 21 (30.4)
pN0 122 (66.7) 48 (69.6)
Adjuvant therapy n (%) 36 (19.7) 13 (18.8)
Positive smoking history n (%) 136 (74.3) 39 (56.5)
Median age years (IQR) 66 (41–90) 69 (43–90)
Median follow-up months (IQR) 15.6 (0.4–142.7) 15.6 (0.6–163.2)
Disease-specific event n (%) 71 (38.8) 33 (47.8)
Death n (%) 45 (24.6) 24 (34.8)
AR expression n (%)
bmedian 85 (46.5) 43 (62.3)
≥median 98 (53.6) 26 (37.7)
TCGA subtype n (%)
TCGA subtype I 67 (36.6) 22 (31.9)
TCGA subtype II 47 (25.7) 13 (18.8)
TCGA subtype III 39 (21.3) 19 (27.5)
TCGA subtype IV 29 (15.9) 13 (18.8)
NA 1 (0.6) 2 (2.9)
Figure 4. Box plot analysis of AR mRNA expression according to
TCGA subtype in the TCGA cohort.
664 Sikic et al. Translational Oncology Vol. 12, No. 4, 2019RNA expression between the two basal subtypes differs almost
gnificantly as well (P = .06).
For analysis of AR expression on survival we used the median AR
RNA expression level (2.83) as the cut-off to define high and low
R expression. This way, no significant association between AR
RNA expression and DFS (P = .11) or OS (P = .54) was observed
Kaplan–Meier analysis (Supplementary Figure 3).
Given that gender-specific differences of the role of AR can be
pected, we additionally accounted for gender in the Kaplan–Meier
alysis. Women with high AR mRNA expression ≥2.83 had
gnificantly worse DFS (P = .03) and OS (P = .02) than womenFigure 3. Correlation of AR mRNA expression with cith low AR mRNA expression b2.83. By contrast, men had no
anges in survival depending on AR expression (Figure 5). These
sults may in part be attributed to adjuvant radio−/chemotherapy, as
.6% (12/42) of the women with AR b2.83 and only 3.7% (1/27)
females with AR ≥2.83 received an adjuvant therapy, while the
stribution of adjuvant therapy was more balanced in male patients
2.4% (19/85) of men with low AR and 17.9% (17/98) of men with
gh AR received adjuvant therapy). We tried to address this problem
separately analyzing women with and without adjuvant therapy.
he subgroup of women without adjuvant chemotherapy (n = 56)
ly revealed a trend towards improved OS and DS when AR mRNA
pression was low, which, however, was not statistically significant.
he subgroup who received adjuvant therapy contained only 13


































Figure 5. Kaplan–Meier analysis for DFS (a) and OS (b) in women as well as DFS (c) and OS (d) in men with MIBC depending on ARmRNA
expression.
Translational Oncology Vol. 12, No. 4, 2019 Sikic et al. 665proved survival was seen here as well (Supplementary Figures 4 and 5).
he small size of these subgroups prevents meaningful analyses and
nclusions. Therefore, a possible bias must be considered when
terpreting our survival analysis of all 69 females.
Finally, multivariable Cox's regression analysis demonstrated
edian AR mRNA expression in women to be an independent
ognostic marker for DFS (L-R Chi2:7.23; P = .007) and OS (L-R
hi2:4.32; P = .04) when stratified for tumor stage, grade, nodal
atus, and age (Figure 6).
Since an association with AR mRNA expression was previously
ggested, we additionally analyzed GATA3 mRNA expression in
IBC by analogy with AR. GATA3 mRNA expression was also
sociated with the TCGA subtype (Chi2 = 146.83; P b .0001)
upplementary Figure 6). Unlike AR however, GATA3 mRNA
pression was significantly associated with gender (Chi2 = 3.97; P =
5), tumor stage (Chi2 = 6.61; P = .03) and showed a negative
sociation with tumor grade (Chi2 = 18.11; P b .0001). Interestingly,
ere was no association between GATA3 mRNA expression andFigure 6. Multivariable Cox's regression analysis for DFS inrvival, irrespective of whether the total or gender-specific cohorts were
alyzed (Supplementary Figures 7, 8 and 9).
iscussion
rception of UCB has changed vastly in recent years. After over two
cades of very little improvement of diagnostic and therapeutic options
8], recent studies demonstrated UCB to be a very heterogenic disease
ith multiple genetic mutations as well as molecular subtypes, offering
w possibilities to classify and treat UCB [20,27,29,30]. Moreover,
cause of gender-specific differences ofUCB, sexual hormones in general
d AR in particular have been discussed as a possible factor in the genesis
d progression of UCB [6]. However, because of conflicting results, the
le of AR inUCB remains unclear [8,13–15]. The differing resultsmight
rtially be attributed to immunohistochemistry as the main means of
termining AR expression in most studies, as immunohistochemistry is
sociated with high inter-observer variability [16]. To avoid the technical
itations of immunohistochemistry in the assessment of AR protein















































































































666 Sikic et al. Translational Oncology Vol. 12, No. 4, 20191 UCB using reverse transcription quantitative real-time polymerase
ain reaction (RT-qPCR) [17]. We found that ARmRNA expression is
sociated with better survival in stage T1 UCB.
Even though immunohistochemistry based studies had contradictory
sults, they consistently report a changing role of AR in UCB with
creasing stage. Therefore, in the present study, we retrospectively
vestigated AR mRNA expression in all stages of UCB within two
dependent cohorts. In the Aarhus cohort, AR mRNA expression was
gher in lower stages, which is most prominent between non-muscle-
vasive and muscle-invasive disease. There were no significant
fferences in AR mRNA expression when comparing stages T2 –
4, which was also the case in the TCGA cohort. Unfortunately, given
at no data on progression was available in both cohorts, it cannot be
ncluded that ARmRNA expression changes during progression from
MIBC toMIBC.However, these results suggest a different role of AR
NMIBC and MIBC, while there seem to be no relevant additional
anges of AR expression within the different stages of MIBC. The
rrent results are comparable to the findings of Boorjan et al. [14].
The high expression of AR mRNA in NMIBC might also be of
erapeutic relevance. Several preclinical studies demonstrated an
proved BCG efficacy in the presence of antiandrogens [31,32]. AR
gradation was shown to recruit monocytes and macrophages that
omote BCG attachment to UCB cells which eventually enhance BCG-
duced UCB cell death through TNF-α release [31]. Unfortunately,
cking any information on BCG therapy and survival, we are not able to
aw any conclusions from our current results. However, high AR
pression in NMIBC might be responsible for patients not responding
BCG therapy. Further clinical studies will be necessary to address
is topic.
Since the available clinicopathological data in the Aarhus cohort were
ited, the analysis was focused on the TCGA cohort, which comprised
ly patients with stage T2 – T4 MIBC. The results were mostly
gative. There was no significant association between AR mRNA
pression with tumor stage, grade or nodal status. Interestingly, there
as also no association between AR expression and age, as change in AR
pression with increasing age might be assumed [33], which is not the
se in the current study. Moreover, no association was found between
R expression and smoking status, which was suggested by a previous
udy [16].
The only statistically significant association was observed between
R mRNA expression and GATA3 mRNA expression as well as the
CGA subtype.
The relation between AR and GATA3 was examined because an
sociation was implicated by previous studies [19,22]. Previous
vestigations demonstrated a protective role of GATA3 expression in
e urinary bladder, as GATA3 was shown to be down-regulated in
othelial carcinoma, high grade urothelial carcinoma andMIBC when
mpared to normal urothelium, low grade urothelial carcinoma and
MIBC, respectively [22]. The current results are in concordance with
evious findings, as we also found an inverse association between
ATA3 expression and tumor grade. Moreover, Li et al. showed that
drogens are capable of decreasing GATA3 expression in normal
othelial cell lines via AR mediation, while no effect of androgens on
ATA3 expression in neoplastic urothelial cells was observed [19]. This
so coincides with our results, since AR and GATA3 expression were
sitively correlated in MIBC in the current study, meaning that AR
d no negative effect on GATA3 expression in bladder cancer. GATA3
ight have a different role in UCB when compared to normal
othelium. Interestingly, although GATA3 demonstrated an associa-on with several clinicopathological features, it had no prognostic
levance regarding survival. However, in concordance with previous
udies [20,29], we observed a significantly higher expression in the
minal TCGA subtypes I and II, confirming GATA3 as an important
arker to distinguish luminal from basal subtypes.
Analysis of the association of AR mRNA expression with the TCGA
btypes in MIBC revealed a significantly lower AR mRNA expression
the two basal subtypes III and IV when compared to the luminal
btypes I and II. The lowest AR expression was in TCGA subtype III,
hich ismainly characterized by high expression of keratins, like KRT5,
RT6a and KRT14 [27]. The current results in MIBC are in contrast
our previous findings in stage T1 bladder cancer, which showed a
atistically significant positive association between high mRNA
pression of AR and KRT5, both of which were associated with
tter survival [17]. On the other hand, other molecular analyses found
e basal subtype to be more aggressive than the luminal subtype in
IBC [20]. Taken together, these findings implicate a lower AR
pression in MIBC, which might contribute to the worse outcome of
sal subtypes inMIBC, while AR targeted therapies for luminalMIBC
ight be considered a possible therapeutic option in the future.
Overall, the most interesting finding of the current analysis is the
nder-specific influence of AR mRNA expression on survival. When
ing AR expression at median level as a cut-off to define high and low
R mRNA expression, 53.6% of male patients and 37.7% of female
tients with MIBC had high expression. While AR expression had no
fect on survival in men, females expressing AR mRNA above median
vel demonstrated significantly worse DFS and OS. These results may
part be attributed to adjuvant radio−/chemotherapy, as 27.9% of
males with low AR expression and only 3.9% of females with high AR
pression received an adjuvant therapy, which has to be considered
hen drawing conclusions from the current results. We tried to address
is problem by separately analyzing women with and without adjuvant
erapy. This way, a trend towards improved survival was seen in both
bgroups when AR mRNA expression was below median level,
though the results were not statistically significant.However, the small
ze of these subgroups prevents meaningful analyses and conclusions.
herefore, a possible bias must be considered when interpreting our
rvival analysis of all 69 females. Nevertheless, considering the poor
sponse of UCB to chemotherapy [34,35], the possible gender-specific
le of AR in female patients withMIBC should not be disregarded and
ould be validated in further studies. The gender-specific difference
garding the association of AR mRNA expression and survival would
especially surprising, because AR mRNA expression does not differ
gnificantly between men and women. This effect might be due to
stinct hormone levels between men and women as well as cross-
actions between AR and other hormonal receptors, which has been
ggested in breast cancer [36]. This way, a different role of high AR
pression in women and men is thinkable, even though AR mRNA
pression does not differ significantly between genders. Nevertheless,
e reasons for the different results in females and males remain unclear
d need further investigation.
Finally, as in NMIBC, the therapeutic relevance of AR expression
MIBC still has to be determined. Recent studies demonstrated a
tter outcome for patients with UCB when treated with antiandro-
ns for concomitant prostate cancer [37]. Another study suggested
improved efficacy of platinum-based chemotherapy when given
gether with antiandrogens [38]. Since AR expression does not
crease with higher tumor stages according to our results, patients
























































Translational Oncology Vol. 12, No. 4, 2019 Sikic et al. 667tiandrogen therapy accompanying chemotherapy. Further studies
e necessary to clarify this topic.
There are several limitations to this study. First, there are the
itations associated with a retrospective study. Some important
formation, like most clinical features in the Aarhus cohort or the
eatment modalities in both cohorts were missing. We decided to
ercome this problem by including only patients with a documented
status as a surrogate for a surgical therapeutic approach in the
CGA cohort, however the exact type and outcome of the surgery
mains unclear, which has to be accounted for when interpreting our
sults regarding survival. Another limitation is the small size and
even composition of the Aarhus cohort while the disproportionate
stribution of adjuvant therapy in females in the TCGA cohort
ight lead to a bias in the survival analysis. Moreover, the diversity of
e two cohorts regarding population, available data and methods
ed for AR mRNA quantification means that a direct comparison of
e two cohorts is not possible. Another possible limitation of mRNA
antification is the potential contamination with non-neoplastic
othelium. While we used only samples containing more than 50%
mor cells by analogy with previous studies in breast cancer [24–26],
contamination cannot be entirely excluded. Finally, no data was
ailable on immunohistochemical staining of the analyzed genes,
hich, however, remains the most readily available form of detection
molecular markers.
In conclusion, by analyzing AR mRNA expression in UCB within
o different cohorts a significantly lower AR mRNA expression was
monstrated in MIBC when compared to NMIBC, with no further
fferences in ARmRNA expression within the various stages ofMIBC.
oreover, AR mRNA expression demonstrated a gender-specific
pact on outcome. Females expressing ARmRNA above median level
d significantly worse DFS. Further studies with larger cohorts are
cessary to clarify the gender-dependent role of AR in UCB.
Supplementary data to this article can be found online at https://doi.org/
.1016/j.tranon.2019.01.005.
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